Chairman of the Board
Fredrik Buch (Swedish, born 1954) joined Pila Pharma in 2016 as Director of the Board due to his significant experience from both clinical work and drug development in the pharma segment as well as profound experience in company start-ups, fund investing and financing. He is Chairman of the Board since 2021.
Fredrik Buch is an orthopaedic surgeon and scientist by training and holds an M.D in medicine (1975) and a PhD from the University of Gothenburg (1985) and has held several clinical research positions in Pharma/Biotech from 1987-1996 including Bristol Myers Squibb, Hoechst, Pharmacia and Pharmacia & Upjohn and is the author of more than 20 scientific publications.
Besides, Fredrik Buch has been head of SEB Healthcare Funds (1997 -2000) and partner at HealthCap (2000-2003). Since 2004 Fredrik has been acting as financial advisor to start-up companies, raising capital and serving on various boards in Sweden and abroad.
Fredrik Buch currently holds Director of the Boards positions in Sweden of Lantmännen Medical AB (since 2005), Lobsor Pharmaceuticals AB (since 2014), Intrance Medical Systems Inc (since 2018), Cytovac AB (since 2019), Tridentify AB (since 2019, Acarix AB (since 2021) and serves as Chairman at Huvudsta Vårdcentral AB (since 2010) and Citadellet AB (since 2016). Fredrik has served on more than 20 boards before joining Pila Pharma including as Chairman of the Board of Follicum (publ).
Share ownership in the company: 21 330 (indirect).